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has been found to be high in patients with chronic schizophrenia. Current evidence shows that
CAD is underdiagnosed in this group. Our study evaluated the prevalence of MS and the risk of
CAD in patients with chronic schizophrenia in a chronic care mental hospital in southern
Taiwan. We included all patients with the diagnosis of schizophrenia or schizoaffective disor-
der. We collected all laboratory, physical examination, psychiatric interview, and chart review
data. We also evaluated the risk of CAD in these patients using the Framingham point system.
There was no significant age difference in the MS prevalence rate in these patients. The young
patients with schizophrenia in our study tended to have a higher prevalence of MS than the
general population. In addition, female patients had a higher prevalence rate of MS than
males. Based on the Framingham point system, we found the 10-year risk of CAD to be higher
among the patients with schizophrenia than in the general population. Our study highlights the
importance of the high risk of MS in both younger and older patients with schizophrenia,
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580 P.-T. Tseng et al.are needed to confirm these findings. Psychiatrists may want to establish more specific and
detailed clinical guidelines for patients with chronic schizophrenia with comorbid physical dis-
eases, especially MS and CAD.
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More than 2,890,000 patients are affected by metabolic
syndrome (MS) in Taiwan [1]. In an epidemiologic surveil-
lance study on the prevalence of hypertension, hypergly-
cemia, and hyperlipidemia in Taiwan using the World
Health Organization 2000 criteria, Chen et al [2] reported
the total prevalence rate of MS to be 15%, with males
having a higher prevalence than females (16.9% vs. 13.3%).
Rates in both sexes were reported to increase with age in
that study (p < 0.001). This increased prevalence in the
older population was also found in a review study by Mal-
hotra et al [3] and a nationwide cross-sectional population-
based Taiwanese study by Hwang et al [1].
Patients with psychiatric illnesses are believed to have a
higher prevalence rate of MS than the general population
[4]. Patients with schizophrenia have been found to be at
higher risk of metabolic disorders including diabetes mel-
litus (DM) and MS, and to have a higher mortality rate
because of coronary artery disease (CAD) [5,6]. The Clinical
Antipsychotics Trials of Intervention Effectiveness (CATIE)
reported the prevalence rate of MS in patients with
schizophrenia to be 51.6% in females and 36.0% in males
[7]. The prevalence of MS has also been found to be higher
in young patients with schizophrenia than in the general
population [8]. Furthermore, the increased risk of mortality
caused by comorbid diseases in patients with severe psy-
chiatric illness has also attracted public health attention
[9]. One study found the increased risk of mortality not to
result from higher suicide risk only but also from physical
diseases such as MS and ischemic heart disease, with
ischemic heart disease found specifically in patients with
schizophrenia [10].
Many reports have attempted to evaluate the risk fac-
tors of MS or factors affecting MS in schizophrenia. The use
of antipsychotics, either briefly or long term, has been
associated with increased body weight [11,12]. Smoking
rate, which is high among patients with schizophrenia [10],
is also a well-known risk factor for cardiovascular disease.
Patients with schizophrenia have been found to have an
abnormal metabolic profiles. First, the negative symptoms
of schizophrenia affect their lifestyles, for example,
including eating and exercise habits [13], which may lead to
the abnormal metabolism of lipids. They have been found
to have lower high density lipoprotein cholesterol (HDL-C),
higher total cholesterol, higher low density lipoprotein
cholesterol (LDL-C), and higher triglyceride than those
without psychiatric illness [14], whereas the rate of diag-
nosis and treatment among these patients are lower than
the general population [15,16]. The diagnosis of schizo-
phrenia might predict MS in these patients. This populationhas also been reported to have a prevalence of DM type II
ranging from 10% to 14% [17]. Fifteen percent of these
patients have been found to have glucose intolerance, a
rate twice as high as that found in the general population
[18]. This is exacerbated by the use of antipsychotics. Along
with increases in the availability of second-generation an-
tipsychotics (SGA) have come increases in the prevalence
of DM in patients with schizophrenia (5.1e14.9%) [17].
Clozapine and olanzapine have been associated with the
highest risk, followed by risperidone, ziprasidone, and ari-
piprazole, which have the least risk [7].
The Framingham Point System Scores (FPSS) tool has
been used in several studies to evaluate the risk of CAD in
patients with schizophrenia, who they report are at higher
risk of CAD [16,19,20]. The FPSS is a widely used rating
scale system for predicting the risk of development of a
coronary event [21] and covers a set of risk factors known
to predict CAD, including age, sex, blood pressure, and lipid
profile. Kang et al [22] found the FPSS CAD risk score to be
applicable in the Taiwanese population. That study defined
cutoff points for risk of a coronary event within 10 years to
be > 20%, 10e20%, and < 10% [22]. In another report dis-
cussing the accuracy of the cardiovascular risk prediction of
the FPSS, the researchers found that the risk equations for
cardiovascular risk estimated by FPSS has been found to
have the same accuracy in Asian cohorts, and thus it can be
used to predict the risk of cardiovascular disease in Asian
groups [23].
This hospital-based cross-sectional study evaluates the
prevalence rate of MS and risk factors for risk for MS and
CAD in patients with schizophrenia or schizoaffective dis-
order treated with antipsychotics.Materials and methods
Patients
In this nonrandomized control study, we recruited 304 pa-
tients with schizophrenia or schizoaffective disorder from a
mental hospital in southern Taiwan from July 2009 to
October 2009. Patients were included if they were 20e75
years old and met criteria for schizophrenia or schizo-
affective disorder set forth in the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition, Text-Revision (DSM-
IV-TR). All patients participated of their own free will and
signed informed consent. “Chronic” schizophrenia or
schizoaffective disorder was defined as being diagnosed
with the schizophrenia or schizoaffective disorder for at
least 2 years. All the patients were interviewed by a psy-
chiatrist and their medical charts were reviewed. All
Table 1 Patient characteristics.
Items Total patients
(N Z 304)
Female
(N Z 148)
Male
(N Z 156)
p
Age (y) 48.23  10.53 47.86  0.49 48.57  10.50 0.56
DM history 40 (13.2) 22 (14.9) 18 (11.5) 0.391a
HTN history 61 (20.1) 26 (17.6) 35 (22.4) 0.289a
Hyperlipidemia history 19 (6.3) 5 (3.4) 14 (9.0) 0.044*,a
Hypertriglyceridemia history 2 (0.66) 1 (0.7) 1 (0.6) 0.970a
CAD history 8 (2.6) 7 (4.7) 1 (0.6) 0.026*,a
CVD history 11 (3.6) 4 (2.7) 7 (4.5) 0.406a
Smoking habit
Never 193 (63.5) 125 (84.5) 68 (43.6) <0.001**,a
Ever, but quit 13 (4.3) 4 (2.7) 9 (5.8)
Yes and still 98 (32.2) 19 (12.8) 79 (50.6)
Alcohol habit
Never 265 (87.2) 143 (96.6) 122 (78.2) <0.001**,a
Ever, but quit 7 (2.3) 2 (1.4) 5 (3.2)
Yes and still 32 (10.5) 3 (2.0) 29 (18.6)
Family history of
DM 13 (4.3) 5 (3.4) 8 (5.1) 0.416a
HTN 14 (4.6) 6 (4.1) 8 (5.1) 0.612a
CVD or CAD 1 (0.4) 1 (0.7) 0 (0) 0.235a
Diagnosis
Schizophrenia 275 (90.5) 132 (89.2) 143 (91.7) 0.462a
Schizoaffective disorder 29 (9.5) 16 (10.8) 13 (8.3)
Illness onset duration (y) 22.49  11.29 21.60  10.99 23.31  11.53 0.186
Present antipsychotics
FGA 57 (18.8) 24 (16.2) 33 (21.2) 0.114a
SGA 189 (62.2) 89 (60.1) 100 (64.1)
FGA þ SGA 58 (19.1) 35 (23.6) 23 (17.4)
Physical examination
BMI (kg/m2) 25.50  4.77 26.43  5.18 24.62  4.18 <0.001**
Waist (cm) 88.69  11.69 89.41  12.14 88.00  11.24 0.30
Blood pressure
SBP (mmHg) 116.48  16.69 113.95  15.90 118.87  17.13 0.01*
DBP (mmHg) 75.71  12.17 75.51  12.03 75.89  12.33 0.79
Biochemistry
Triglyceride (mg/dL) 102.76  64.37 101.28  48.21 101.28  48.21 0.70
Fasting blood sugar (mg/dL) 89.36  24.17 94.28  28.89 84.69  17.46 < 0.001**
HDL-C (mg/dL) 33.00  10.90 34.94  11.51 31.15  9.97 < 0.001**
Total cholesterol (mg/dl) 171.93  8.75 170.95  39.34 172.87  3 8.28 0.67
Data are presented as n (%) or mean  SD.
* p < 0.05.
** p < 0.001.
BMI Z body mass index; BW Z body weight; CAD Z coronary artery disease; CVD Z cardiovascular disease; DBP Z diastolic blood
pressure; DM Z diabetes mellitus; FGA Z first-generation antipsychotics; HDL-C Z high-density lipoprotein cholesterol;
HTN Z hypertension; SBP Z systolic blood pressure; SD Z standard deviation; SGA Z second-generation antipsychotics.
a Chi-square test.
MS and risk of CAD in chronic schizophrenia 581available chart records, laboratory data, and interview
records were screened for indications of physical illness.
The protocol for this study was approved by the Institu-
tional Review Board of our hospital.Data collection
We collected basic demographic data, data on psychotropic
agents use and use of any medicine that has an effect on
glucose tolerance, and laboratory data. Body weight wasassessed within 2 hours of the patient wake-up. We calcu-
lated the FPSS using the National Cholesterol Education
Program 2001 edition (NCEP 2001 edition), which includes
items on age, sex, HDL-C, total cholesterol, smoking habit,
and systolic blood pressure. We chose the cutoff point of risk
<10% to categorizepatients into the low risk groupand 10%
to categorized them intomoderate-high risk group according
to a previous report by Kang et al [22].
Body mass index (BMI) was calculated as body weight
(kg) divided by the square of body height (m) and presented
as units of kg/m2. We subdivided patients into groups
Table 2 Prevalence rate of metabolic syndrome.
Items Total
(n Z 304)
Female
(n Z 148)
Male
(n Z 156)
p
Patients met criteria (%) 126 (41.4) 68 (45.9) 58 (37.2) 0.121a
Average no. of abnormal criteria 2.29  1.12 2.49  1.07 2.10  1.13 0.002*
Number of patients with abnormal criteria
Waist >90 cm in males; > 80 cm in females 190 (62.5) 121 (81.8) 69 (44.2) < 0.001**,a
SBP  130 mmHg, DBP  85 mmHg or Rx 123 (40.5) 50 (33.8) 73 (46.8) 0.021*,a
HDL-C < 40 mg/dL in males; < 50 mg/dL in females or Rx 270 (88.8) 134 (90.5) 136 (87.2) 0.353a
Fasting blood sugar  110 mg/dL or Rx 69 (22.7) 41 (27.7) 28 (17.9) 0.042*,a
TG  150 mg/dL or Rx 63 (20.7) 27 (18.2) 36 (23.1) 0.299a
Note. From metabolic syndrome criteria of the Health Promotion Administration, Taiwan, 2006 edition [24].
* p < 0.05.
** p < 0.001.
DBP Z diastolic blood pressure; HDL-C Z high-density lipoprotein cholesterol; MS Z metabolic syndrome; Rx Z pharmacologic
treatment; SBP Z systolic blood pressure; TG Z triglyceride.
a Chi-square test.
582 P.-T. Tseng et al.according to their BMI, using the criteria of the Ministry of
Health and Welfare, Taiwan (lean: BMI <18.5; normal:
18.5  BMI < 24; overweight: 24  BMI < 27; mild obesity:
27  BMI < 30; moderate obesity: 30  BMI < 35; and se-
vere obesity: BMI  35).Definition of MS
MS was defined using criteria established by the Health
Promotion Administration, Taiwan, 2006 edition (HPAT-
2006) [24]. These criteria include: (1) waist > 90 cm in
males, > 80 cm in females; (2) systolic blood pressure
 130 mmHg and diastolic blood pressure  85 mmHg or
under antihypertensive agent treatment; (3) HDL-C
<40 mg/dL in males and <50 mg/dL in females or under
antihyperlipidemia agent treatment; (4) fasting blood
sugar  110 mg/dL or under diabetic treatment; and (5)
triglyceride  150 mg/dL or under antihypertriglyceridemiaTable 3 Prevalence rate of metabolic syndrome by age group.
Abnormal data,
patient
Waist obesity (> 90 cm in males; > 80 cm in fe
Blood pressure
HDL-C
Fasting sugar
TG
HPAT-2006 Patients with MS
No. of abnormal criteria
Data are presented as n (%) or mean  SD.
* p < 0.05.
HDL-C Z high-density lipoprotein cholesterol; HPAT-2006 Z H
MS Z metabolic syndrome; SD Z standard deviation; TG Z triglycer
a Chi-square test.agent treatment. Patients were considered to have MS if
they met three or more of the criteria.
Statistical analysis
Patient characteristics were analyzed descriptively. Chi-
square test, one-way analysis of variance, and analysis of
covariance were used to analyze the relationship between
patient characteristics and MS.
One-way logistic regression was used to evaluate risk
factors for MS in our patients. These included age, sex
(male), the psychiatric illness duration, BMI, current
smoking habit, personal history of physical illness (including
DM, hypertension, dyslipidemia, cardiovascular disease,
and CAD), family history of physical illness (including DM,
hypertension, dyslipidemia, cardiovascular disease, and
CAD), current antipsychotics use (First generation antipsy-
chotics (FGA), second generation antipsychotics (SGA), or
FGA þ SGA), combined with other psychotropic agentsAge
20e39 y
(n Z 57)
40e59 y
(n Z 208)
60e79 y
(n Z 39)
p
males) 71.9 61.5 53.8 0.175a
36.8 38.0 59.0 0.041a,*
89.5 88.5 89.7 0.958a
10.5 24.0 33.3 0.023a,*
22.8 21.2 15.4 0.654a
24 (42.1) 86 (41.3) 16 (41.0) 0.993a
2.28  1.11 2.27  1.14 2.41  0.99 0.782
ealth Promotion Administration, Taiwan, 2006 edition [24];
ide.
Table 4 Logistic regression of risk factors for MS according to HPAT-2006.
Items Without MS (n Z 178) With MS (n Z 126) Crudee
OR (95% CI)
Adjustedf
OR (95% CI)
Agea (y) 48.22  10.38 48.23  10.79 1.00 (0.98e1.02) 1.01 (0.98e1.05)
Sexb: male 98 (55.1) 58 (46.0) 0.70 (0.44e1.10) 0.67 (0.34e1.33)
Illness onset durationa (y) 22.10  11.15 23.02  11.50 1.01 (0.99e1.03) 1.02 (0.98e1.05)
BMIa (kg/m2) 23.70  4.40 28.04  4.08 1.27 (1.19e1.35)** 1.25 (1.16e1.36)**
Present smoking habitb: yes 52 (29.2) 46 (36.5) 1.39 (0.86e2.26) 1.63 (0.79e3.35)
Physical illness historyb,c: yes 32 (18.0) 73 (57.9) 6.28 (3.73e10.58)** 7.75 (3.95e15.20)**
Family history of physical illnessb,c,d: yes 11 (6.6) 10 (8.8) 1.36 (0.56e3.33) 0.63 (0.20e2.05)
Currently used psychotropic agents
FGAb 35 (19.7) 22 (17.5) Reference Reference
SGAb 109 (61.2) 80 (63.5) 1.17 (0.6e2.14) 1.38 (0.6e3.09)
FGA þ SGAb 34 (19.1) 24 (19.0) 1.12 (0.5e2.37) 1.13 (0.4e3.10)
Anxiolytics/hypnoticsb 136 (76.4) 85 (67.5) 0.64 (0.3e1.07) 0.57 (0.2e1.12)
Antidepressantsb 6 (3.4) 3 (2.4) 0.70 (0.1e2.85) 0.78 (0.1e6.14)
Mood stabilizerb 23 (12.9) 24 (19.0) 1.59 (0.8e2.96) 1.45 (0.6e3.23)
Note. From the Health Promotion Administration, Taiwan, 2006 edition criteria [24].
*p < 0.05.
**p < 0.001.
MS Z metabolic syndrome; HPAT-2006 Z Health Promotion Administration, 2006 edition; FGA Z first-generation antipsychotics;
SGA Z second-generation antipsychotics; BMI Z body mass index; SD Z standard deviation.
a Presented as mean  SD.
b Presented as number (%).
c Physical illness history and family history of physical illness: history of diabetes mellitus, hypertension, hyperlipidemia, or coronary
heart disease, cardiovascular disease.
d Missing value Z 23.
e Simple logistic regression.
f Multiple conditional logistic regression.
MS and risk of CAD in chronic schizophrenia 583(anxiolytics, antidepressants, or mood stabilizers). To
compare group differences in 10-year risk of CAD, patients
were stratified into those at low risk (FPSS < 10%) and
moderate-high risk (FPSS  10%).
All statistical operations were performed using Statisti-
cal Package for the Social Sciences (SPSS) version 12.0 (SPSS
version 12.0) (SPSS Inc., Chicago, IL, USA). Significance was
defined as p < 0.05.
Results
Demographic data
A total of 304 patients (148 female patients and 156 male
ones) were recruited in our study and the average age of
these patients was 48.23  10.53 years. Our male patients
had a higher prevalence rates of hypertension, hyperlip-
idemia, and cardiovascular disease than our female pa-
tients, whereas our female patients had a higher
prevalence rates of DM and CAD. However, the only sig-
nificant differences in these measures were found in
hyperlipidemia and CAD (p Z 0.044 and p Z 0.026,
respectively; Table 1).
MS-related data
The average BMI in our patients was higher than that re-
ported for the general population (25.50  4.77 kg/m2,
general population: 24.0 kg/m2) [1,2] with females having asignificantly higher BMI than males in this study (p < 0.001).
The female patients in our study also had significantly
higher serum HDL-C and fasting blood sugar levels
(p < 0.001, p < 0.001, separately).
MS prevalence
The prevalence rates of abnormal MS-related criteria
among our sample from highest prevalence to lowest were
low HDL-C (88.8%), waist obesity (62.5%), hypertension
(40.5%), high fasting blood sugar (22.7%), and high triglyc-
eride level (20.7%). Female patients had higher prevalence
rates for waist obesity and high fasting blood sugar than the
males (p < 0.001 and pZ 0.042, respectively), whereas the
males had a higher prevalence rate of hypertension
(p Z 0.021; Table 2).
Prevalence of MS by age
Although no significant age difference was found in the
prevalence rate of MS, based on HPAT-2006 criteria (data
not shown), high blood pressure and high fasting blood
sugar rates were found to increase significantly with age
(p Z 0.041 and p Z 0.023, respectively, Table 3).
Logistic regression analysis of the risk factors for MS
In our logistic regression analysis of factors listed in HPAT-
2006, we found the only two risk factors significantly
Table 5 Ten-year risk of coronary artery disease.
Items 10-year risk of coronary
artery disease (Framingham
point system)
pb
Unadjusted
mean
Adjusted
meana
Onset of illness
< 10 y 2.54  4.12 5.31  0.88 0.330
10e20 y 3.84  5.43 5.72  0.57
 20 y 8.40  8.35 6.63  0.45
BMI
Underweight 6.07  8.91 5.44  1.40 0.001*
Normal 6.00  6.60 4.45  0.52
Overweight 7.37  8.95 7.22  0.64
Obese 5.60  7.10 7.22  0.50
Family history of physical illness
No 5.93  7.37 5.89  0.32 0.164
Yes 7.10  7.82 7.54  1.14
Currently used antipsychotics
FGA only 8.47  9.32 7.52  0.72 0.079
SGA only 6.13  7.27 6.04  0.39
FGA þ SGA 4.09  5.39 5.28  0.71
Currently used nonantipsychotics
Anxiolytics/hypnotics
No 6.61  8.26 6.74  0.59 0.254
Yes 6.00  7.17 5.95  0.36
Antidepressants
No 6.18  7.46 6.17  0.59 0.254
Yes 6.00  7.17 5.95  0.36
Mood stabilizer
No 6.25  7.65 6.11  0.34 0.685
Yes 5.67  6.51 6.46  0.80
Metabolic syndrome (HPAT-2006)
No 4.80  6.13 4.56  0.38 < 0.001**
Yes 8.06  8.70 8.40  0.45
* p < 0.05.
** p < 0.001.
BMIZ body mass index; FGAZ first-generation antipsychotics;
HPAT-2006 Z Health Promotion Administration, Taiwan, 2006
edition; SGA Z second-generation antipsychotics.
a Adjusted for age and sex.
b The comparison result of the adjusted mean.
Figure 1. The 10-year risk of coronary artery disease in pa-
tients: effect of sex by age group. The male patients had a
significantly higher 10-year risk of coronary heart disease in
each age group when adjusting for age only. Adjusted for age; *
p < 0.05.
584 P.-T. Tseng et al.associated with MS to be BMI and personal history of
physical illness, with BMI having an odds ratio (95% con-
fidence interval) of 1.25 (1.16e1.36) and personal history
of physical illness 7.72 (3.93e15.13) (both p < 0.05;
Table 4).
Relationship between FPSS and MS
In order to reduce confounding, we chose age and sex to
include as covariants in our analysis of covariance of FPSS
data. As can be seen in the pre- and postadjusted results
listed in Table 5, overweight and obese patients had a
significantly higher risk of CAD than the other two groups
(p Z 0.001). Patients with MS had a significantly higher
risk of CAD, according to both criteria (p < 0.001). Also,
the risk of CAD was significantly higher in patients whosmoked than those who did not in the 20e39-year-olds and
40e59-year-olds, but not in 60e79-year-olds. The 10-year
CAD risk in males was significantly higher than in the fe-
males in each age group, after adjusting for age only
(Figure 1).
We found no significant difference in usage of psycho-
tropic medicines (such as antipsychotics, anxiolytics/hyp-
notics, antidepressants, or mood stabilizers) between the
low and moderate-high risk groups (Table 6).
Discussion
The main finding in our study is that there was no significant
difference in the prevalence rate of MS between young,
middle-aged, and older patients with schizophrenia, though
the young patients with schizophrenia in our study seem to
have a higher prevalence rate of MS than similarly aged
young adults in the general population (42.1% of patients
aged 20w39 years in our study; 15.0% in the Taiwanese
general population of a similar age) [2]. We also found that
the female patients had a higher prevalence rate of MS and
CAD than the males. This finding is in contrast to a report by
Chen et al [2], in which the prevalence rate of MS in the
Taiwanese community was higher among males than fe-
males, increasing with age. This discrepancy might be due
to the different sample sources in our study and the report
by Chen et al [2]. However, our study results are in
agreement with the prevalence rate of MS in a previous
report [2], which was higher than in the general population.
Also, the higher prevalence rate among female patients
with schizophrenia (45.9% in females, 30.1% in males) in our
study is similar to the results reported in the CATIE study
(51.6% in females, 36.0% in males) [7].
The higher prevalence rate of MS in our young patients
(20e39 years old) compared to the general population
suggests that MS might develop earlier in patients with
schizophrenia than in the general population. An increasing
number of reports suggest that the prevalence rate of MS
among antipsychotics-naı¨ve patients with schizophrenia is
higher than in the general population [25e27]. Also, despite
the relationship between antipsychotics use and MS found
in other reports [12,28,29], the use of antipsychotics (FGA,
SGA, or FGA þ SGA) in our study was not found to have
significant association with MS in our regression model.
Therefore, it may be that the high prevalence rate of MS
Table 6 Ten-year risk of coronary artery disease and
comparison of medication usage.
Items 10-year risk of coronary
artery disease
(Framingham point system)
pa
<10%
(n Z 212)
10%
(n Z 87)
Current antipsychotics usage
FGA 32 (15.1) 23 (26.4) 0.066
SGA 136 (64.2) 50 (57.5)
FGA þ SGA 44 (20.8) 14 (16.1)
Current non-antipsychotics usage
Anxiolytics/hypnotics 154 (72.6) 63 (72.4) 0.968
Antidepressants 7 (3.3) 2 (2.3) 0.645
Mood stabilizer 31 (14.6) 15 (17.2) 0.569
Data are presented as n (%).
FGA Z first-generation antipsychotics; SGA Z second-genera-
tion antipsychotics.
a Chi-square test.
MS and risk of CAD in chronic schizophrenia 585among our young patients with schizophrenia might result
not only from the usage of antipsychotics but also from
some other etiologies, such as maladaptive lifestyles or
systemic inflammation [30e32]. Because we did not
directly compare our patients with the general population,
this hypothesis needs further confirmation. This study did
not take the duration of antipsychotics usage into consid-
eration, and thus we cannot completely rule out the effect
of antipsychotics usage on MS.
This study found the main risk factors for MS to be BMI
and a history of physical illness (DM, hypertension, hyper-
lipidemia, CAD, and cardiovascular disease). We did not
find any significant association for age, smoking habit, and
male sex with MS. This finding is partially consistent with
previous reports from Taiwan, in both the general popula-
tion [1] and in patients with schizophrenia [33].
This study also found MS and BMI to be significant risk
factors predicting 10-year risk of CAD (p < 0.001 and
p Z 0.001, respectively), after adjusting for age and sex.
Our finding of an increased risk of CAD in patients with MS
(Table 5) is consistent with other reports [34,35]. MS has
been reported to affect the clinical outcome of patients
with schizophrenia not only because it is a direct compli-
cation, but also because it affects neurocognitive function
in these patients [36] and quality of life in patients with
psychosis [37]. Average BMI seemed to be higher in our
patients than that reported for the general population
[1,2]. It should be noted that obesity may be considered
as a risk factor solely for mortality, despite metabolic
health [38].
Our study has some limitations. First, it is a cross-
sectional study and thus we could not make a direct
inference with regard to causal relationships. Second, it
lacked previous records of the diet and activities of the
patients. Third, although all the patients in our study lived
in the same chronic care institute and had the same diet
from the central kitchen, we could not rule out the possible
bias effect of diet. Additionally, because all the patients
came from the same chronic care institute, our studyresults cannot be applied to all patients with chronic
schizophrenia in Taiwan. Fourth, we did not evaluate the
history of antipsychotics use and the severity of mental
disease in our study, which might have influenced the re-
sults. Fifth, we did not directly compare the prevalence
rate of MS between the young people in our study and in the
general population [1,2]. Finally, the FPSS is based on
Caucasian samples in the United States, and research on
the reliability and validity of its use in Asian groups found
the possibility of overestimation in these groups [23]. There
has not yet been a cohort study in Taiwan, both in the
general population and among patients with schizophrenia,
so there is still some uncertainty with regard to its validity
and reliability in this population.
In conclusion, this study highlights the importance of the
high prevalence rate of MS in patients with schizophrenia,
both young and old. Clinicians may want to pay more
attention to regular screening for MS in these patients, with
or without antipsychotics use, because the occurrence of
MS may have a negative effect on the clinical outcome of
patients with schizophrenia, either by direct complication
or through its effect on neurocognition.Acknowledgments
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